+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Gastrointestinal transit and release of 5-aminosalicylic acid from 153Sm-labelled mesalazine pellets vs. tablets in male healthy volunteers



Gastrointestinal transit and release of 5-aminosalicylic acid from 153Sm-labelled mesalazine pellets vs. tablets in male healthy volunteers



Alimentary Pharmacology & Therapeutics 17(9): 1163-1169



Background: Mesalazine (5-aminosalicylic acid)-containing formulations, designed to optimize drug delivery to the ileo-caecal region, represent a cornerstone in the treatment of inflammatory bowel diseases. Aim: To test, by means of pharmaco-scintigraphy, whether novel mesalazine-containing pellets release 5-aminosalicylic acid in the same target region as mesalazine tablets (Salofalk). Methods: Fourteen healthy male volunteers received a single dose of either pellets or tablets containing 500 mg of mesalazine and 2 mg of 152Sm2O3 with a 1-week washout period. The gastrointestinal transit of 153Sm, incorporated into the formulations, was followed by gamma-scintigraphy. Mesalazine release was verified by assessing 5-aminosalicylic acid plasma pharmacokinetics. Results: The formulations reached the ileo-caecal target region almost at the same time (3.3 +- 1 and 3.8 +- 1 h for pellets and tablets, respectively). Plasma 5-aminosalicylic acid tmax values were comparable and corresponded to the time during which the formulations were located in the target region. Plasma AUC values were significantly lower for pellets, which might be explained by a more prolonged release of 5-aminosalicylic acid. Conclusions: Novel mesalazine pellets and Salofalk tablets release active 5-aminosalicylic acid in the same target region and pass through the gastrointestinal tract under fasting conditions in healthy volunteers in a comparable time. Prom a comparison of in vitro dissolution and plasma concentration data, a slower and more prolonged release of 5-aminosalicylic acid from pellets is suggested.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 010697400

Download citation: RISBibTeXText

PMID: 12752353

DOI: 10.1046/j.1365-2036.2003.01564.x


Related references

5-aminosalicylic acid release from a new controlled-release mesalazine formulation during gastrointestinal transit in healthy volunteers. Alimentary Pharmacology & Therapeutics 23(1): 137-144, 2006

Disposition of 5-aminosalicylic acid from 5-aminosalicylic acid-delivering drugs during accelerated intestinal transit in healthy volunteers. Scandinavian Journal of Gastroenterology 24(10): 1179-1185, 1989

Gastrointestinal pH and Transit Time Profiling in Healthy Volunteers Using the IntelliCap System Confirms Ileo-Colonic Release of ColoPulse Tablets. Plos One 10(7): E0129076, 2016

Gastrointestinal transit and release of mesalazine tablets in patients with inflammatory bowel disease. Scandinavian Journal of Gastroenterology. Supplement 172: 47-51, 1990

Relationship between systemic drug absorption and gastrointestinal transit after the simultaneous oral administration of carbamazepine as a controlled release system and as a suspension of nitrogen 15 labelled durg to healthy volunteers. British Journal of Clinical Pharmacology 32(5): 573-580, 1991

Multiple absorption patterns of mesalazine from two gastroresistant tablets in healthy male volunteers: Effects of food and formulation. Clinical Drug Investigation 21(4): 295-305, 2001

Relationship between systemic drug absorption and gastrointestinal transit after the simultaneous oral administration of carbamazepine as a controlled-release system and as a suspension of 15N-labelled drug to healthy volunteers. British Journal of Clinical Pharmacology 32(5): 573-579, 1991

Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis - results from a randomized-controlled trial. Alimentary Pharmacology and Therapeutics 20(11-12): 1353-1363, 2004

Gastrointestinal transit of technetium-99m labelled oral dosage forms of sucralfate in healthy volunteers. International Journal of Pharmaceutics 96(1-3): 183-188, 1993

Gastrointestinal transit of 99mTc-labelled oral dosage forms of sucralfate in healthy volunteers. International Journal of Pharmaceutics 96(1-3): 183-188, 1993

Suprofen sustained release kinetics in healthy male volunteers. 2nd communication: a multiple dose steady-state kinetics of suprofen sustained release tablets during 6 days in healthy male volunteers. Arzneimittel-Forschung 36(6): 949-954, 1986

Gastrointestinal transit of an enteric-coated delayed-release 5-aminosalicylic acid tablet. Alimentary Pharmacology and Therapeutics 1(3): 209-216, 1987

Bioavailability of a novel diltiazem HC1 once-daily extended-release capsule formulation relative to immediate-release tablets in healthy male volunteers. Pharmaceutical Research (New York) 11(10 SUPPL ): S445, 1994

Scintigraphic study of gastrointestinal transit and disintegration sites of mesalazine tablets labeled with technetium-99m. Scandinavian Journal of Gastroenterology 28(9): 783-785, 1993

Maintenance treatment of crohns disease comparative study of 4 aminosalicylic acid and 5 aminosalicylic acid claversal slow release tablets. Gastroenterology 102(2 PART 2): A692, 1992